Search research articles
Contact Us
Filters
Showing results (31-40 of 65) with videos related to
Page
of 7
Sort By:
Multiple Sclerosis and Related Disorders
|
September 20, 2016
Brain health: time matters in multiple sclerosis
Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 28, 2015
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force
Marc K Walton, John H Powers, Jeremy Hobart, et al.
BMC Neurology
|
March 28, 2024
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland
Ashvin Kuri, David E Henshall, Daoud Chaudhry, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
June 27, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, et al.
Health Technology Assessment (Winchester, England)
|
February 14, 2015
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
Susan Ball, Jane Vickery, Jeremy Hobart, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 19, 2017
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force
John H Powers, Donald L Patrick, Marc K Walton, et al.
Multiple Sclerosis and Related Disorders
|
December 6, 2021
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
Ide Smets, David Holden, Lucia Bianchi, et al.
CNS Drugs
|
December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Therapeutic Advances in Neurological Disorders
|
October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Practical Neurology
|
November 12, 2024
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance
Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 65) with videos related to
Sort By:
Page
of 7
Multiple Sclerosis and Related Disorders
|
September 20, 2016
Brain health: time matters in multiple sclerosis
Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 28, 2015
Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force
Marc K Walton, John H Powers, Jeremy Hobart, et al.
BMC Neurology
|
March 28, 2024
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland
Ashvin Kuri, David E Henshall, Daoud Chaudhry, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
June 27, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, et al.
Health Technology Assessment (Winchester, England)
|
February 14, 2015
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
Susan Ball, Jane Vickery, Jeremy Hobart, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 19, 2017
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force
John H Powers, Donald L Patrick, Marc K Walton, et al.
Multiple Sclerosis and Related Disorders
|
December 6, 2021
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
Ide Smets, David Holden, Lucia Bianchi, et al.
CNS Drugs
|
December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Therapeutic Advances in Neurological Disorders
|
October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Practical Neurology
|
November 12, 2024
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance
Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, et al.
Page
of 7